Therapeutic Escalation and Biologic Selection in Psoriasis

Severity Assessment and Treatment Triggers

• Mild disease is defined as body‑surface‑area (BSA) ≤ 10 % and Psoriasis Area and Severity Index (PASI) ≤ 10 and Dermatology Life Quality Index (DLQI) ≤ 10. Moderate‑to‑severe disease is BSA > 10 % or PASI > 10 and DLQI > 10. High‑impact sites (face, scalp, palms, soles, flexures, genitals, nails) with functional or psychological impairment are classified as severe regardless of BSA or PASI scores. (British Association of Dermatology) 1

• Escalation to biologic therapy is recommended when both methotrexate and cyclosporine have failed, are not tolerated, or are contraindicated and the patient’s DLQI > 10 or clinically relevant depressive/anxiety symptoms are present. (British Association of Dermatology) 1

Phototherapy Recommendations (Systemic‑Level Alternatives)

• Narrowband UVB should be initiated at ≈ 70 % of the patient’s minimum phototoxic dose; subsequent doses are increased by 40 % if no erythema occurs, by 20 % if only slight erythema appears, and are held if erythema exceeds slight. Treatments are given 2–3 times per week, never more frequently than every 48 hours, for a typical course of 8–10 weeks. (British Association of Dermatology) 2

• PUVA (psoralen + UVA) is recommended as the first‑line systemic option when phototherapy alone is insufficient, given its relatively low toxicity among systemic agents. (British Association of Dermatology) 2

First‑Line Biologic Agents (Adults)

Response Assessment and Treatment Modification

• Timing of initial response evaluation:

• Continuation criteria: Maintain therapy when PASI reduction ≥ 75 % from baseline.

• Modification criteria:

• Switching biologics is indicated for:

• Inadequate response to a second or later biologic:

Rapidly Relapsing Disease

• When disease relapses to > 50 % of baseline severity within 3 months after a treatment course that cannot be continued long‑term, earlier initiation of biologic therapy is advised. (British Association of Dermatology) 1

Medications to Avoid in Psoriasis

• Systemic corticosteroids are contraindicated because abrupt withdrawal can precipitate erythrodermic, generalized pustular, or highly unstable psoriasis. (British Association of Dermatology) 5

• Lithium, chloroquine, and mepacrine may cause severe, potentially fatal exacerbations of psoriasis and should be avoided. (British Association of Dermatology) 5

Practical Tips for Topical Failure

• Failure of one topical agent does not predict failure of another; clinicians should trial alternative topicals before escalating to systemic therapy. (British Association of Dermatology) 5

Psoriasis Management Guidelines

Introduction to Psoriasis Treatment

• The American Academy of Dermatology recommends initiating treatment with high-potency topical corticosteroids combined with calcipotriol for mild psoriasis, achieving 58-92% clearance rates 6

Topical Therapy for Mild Psoriasis

• Apply high-potency topical corticosteroids twice daily to thick plaques for maximum 2-4 weeks, with a synergistic effect when combined with calcipotriol 6, 7
• Use low-potency corticosteroids or topical calcineurin inhibitors on sensitive areas, such as the face and genitals, to minimize atrophy risk 6, 7
• Add tazarotene to moderate-to-high potency corticosteroids for body plaques to reduce irritation and enhance efficacy 6, 7

Systemic Therapy for Moderate-to-Severe Psoriasis

• Escalate to systemic therapy when body surface area involvement exceeds 5%, or when there is an inadequate response to optimized topical therapy after 8 weeks 6
• Phototherapy, such as PUVA, is considered a first-line systemic treatment, with a starting dose of 70% of minimum phototoxic dose, and increasing successive doses by 40% if no erythema 8, 9
• Conventional systemic agents, such as methotrexate, acitretin, and cyclosporin, have response times of 2-6 weeks, but require regular monitoring and have contraindications, such as pregnancy and significant hepatic damage 8, 9

Biologic Therapy for Moderate-to-Severe Psoriasis

• Biologics, such as adalimumab, can be combined with methotrexate or topical high-potency corticosteroids, and achieve treatment goals in 68.2-79.3% of patients by week 16 9
• Important safety considerations for biologics include screening for active or latent tuberculosis, hepatitis B, and fungal infections, as well as increased risk of serious infections and cancer 9

Special Considerations for Pustular Psoriasis

• Infliximab demonstrates rapid and often complete disease clearance for generalized pustular psoriasis, and should be considered first-line biologic therapy, with standard dosing of 5 mg/kg infused at weeks 0, 2, and 6, then every 8 weeks thereafter 9
• Avoid systemic corticosteroids in pustular psoriasis due to risk of disease exacerbation upon discontinuation, and consider acitretin as an alternative treatment option 9

Medications to Avoid

• Never prescribe systemic corticosteroids for psoriasis, as they can precipitate erythrodermic psoriasis, generalized pustular psoriasis, or very unstable psoriasis when discontinued 9, 7
• Other medications that worsen psoriasis include lithium, chloroquine, and mepacrine, which may cause severe, potentially fatal deterioration 10, 7

Common Pitfalls

• Perceived "tachyphylaxis" to topical corticosteroids is often due to poor patient adherence rather than true receptor down-regulation, and addressing compliance issues is crucial before switching therapies 7
• Patients who fail to respond to one topical agent may respond to another, and trial alternative topical agents before escalating to systemic therapy 10, 7

Management of Psoriasis with Systemic and Topical Therapies

Topical Therapy Considerations

• The British Medical Journal recommends implementing periods each year when alternative treatments are employed to prevent tachyphylaxis, with a limit on moderate-potency corticosteroid use to maximum 100g per month 11, 12

Systemic Therapy Indications

• Extensive chronic plaque psoriasis in elderly or infirm patients may require systemic treatment, according to the British Medical Journal 13
• Severe psoriatic arthropathy is an indication for systemic therapy, as recommended by the British Medical Journal 14

Systemic Therapy Selection

• The British Medical Journal suggests photochemotherapy (PUVA) as the least toxic systemic agent and should be considered first-line systemic treatment, with a start dose at 70% of minimum phototoxic dose and increased successive doses by 40% of the preceding dose if no erythema develops 12, 14

Conventional Systemic Agents

• The American Academy of Dermatology guidelines provide detailed guidance on methotrexate, which has been FDA-approved since 1972 and works through multiple mechanisms including inhibition of dihydrofolate reductase and increasing endogenous adenosine, with absolute contraindications including pregnancy, breastfeeding, wish to father children, significant hepatic damage, anemia, leucopenia, thrombocytopenia 15, 11

Alternative Topical Options

• The British Medical Journal recommends starting with 0.5-1.0% crude coal tar in petroleum jelly and increasing concentration every few days to maximum 10%, as an alternative topical option when first-line fails 13
• Dithranol (Anthralin) can be started at 0.1-0.25% concentration and increased in doubling concentrations as tolerated, with short contact mode leaving on skin for only 15-45 minutes every 24 hours, according to the British Medical Journal 13